Combined strategies following surgical drainage for perianal fistulizing Crohn's disease: failure rates and prognostic factors

被引:6
|
作者
Herissay, A. [1 ]
Siproudhis, L. [2 ]
Le Balc'h, E. [1 ]
L'Heritier, A. Merlini [1 ]
Dewitte, M. [1 ]
Wallenhorst, T. [1 ]
Bouguen, G. [2 ]
Brochard, C. [2 ]
机构
[1] Univ Rennes, CHU Rennes, Rennes, France
[2] Univ Rennes, Inst NUMECAN Nutr Metab & Canc, CHU Rennes, CIC1414,INSERM, Rennes, France
关键词
Perianal fistulizing Crohn's disease; fistulotomy; immunosuppressants; NATURAL-HISTORY; INFLIXIMAB; CLASSIFICATION; METHOTREXATE; CONSENSUS; PERINEAL; FISTULAS; THERAPY; COUNTY; ANO;
D O I
10.1111/codi.15241
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aim The medico-surgical strategy for the treatment of perianal fistulizing Crohn's disease (CD) following surgical drainage remains challenging and debated. Our aims were to describe the failure rate of therapeutic interventions after drainage of the fistula tract and determine the factors associated with failure to optimize medico-surgical strategies. Method All consecutive patients with perianal fistulizing CD who underwent surgical drainage with at least a 12-week follow-up were included. Failure was defined as the occurrence of at least one of the following items: abscess recurrence, purulent discharge from the tract, visible external opening and further drainage procedure(s). Results One hundred and sixty-nine patients were included. The median follow-up was 4.0 years. The cumulative failure rates were 20%, 30% and 36% at 1, 3 and 5 years, respectively. The cumulative failure rates in patients who had sphincter-sparing surgeries or seton removal were significantly higher than in those who had a fistulotomy. Anterior fistula [hazard ratio (HR) = 2.52 (1.13-5.61),P = 0.024], supralevator extension [HR = 20.78 (3.38-127.80),P = 0.001] and the absence or discontinuation of immunosuppressants after anal drainage [HR = 3.74 (1.11-12.5),P = 0.032] were significantly associated with failure in the multivariate analysis model. Conclusion Combined strategies for perianal fistulizing CD lead to a failure rate of 36% at 5 years. Where advisable, fistulotomy may be preferred because it has a lower rate of recurrence. The benefits of immunosuppressants require a dedicated prospective randomized trial.
引用
收藏
页码:159 / 168
页数:10
相关论文
共 50 条
  • [31] Perianal Fistulizing Crohn’s Disease: No Shortcuts to a Deep Understanding of the Disease
    Jana G. Hashash
    Fadi H. Mourad
    Digestive Diseases and Sciences, 2021, 66 : 1392 - 1393
  • [32] Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease
    Yang, Bo-Lin
    Chen, Yu-Gen
    Gu, Yun-Fei
    Chen, Hong-Jin
    Sun, Gui-Dong
    Zhu, Ping
    Shao, Wan-Jin
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (08) : 2475 - 2482
  • [33] Editorial: Abdominal and Perianal Fistulizing Crohn's Disease: Imaging, Surgical Techniques and Basic Research
    Luglio, Gaetano
    Tropeano, Francesca Paola
    Pagano, Gianluca
    Cricri, Michele
    FRONTIERS IN SURGERY, 2022, 9
  • [34] Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease
    Bo-Lin Yang
    Yu-Gen Chen
    Yun-Fei Gu
    Hong-Jin Chen
    Gui-Dong Sun
    Ping Zhu
    Wan-Jin Shao
    World Journal of Gastroenterology, 2015, 21 (08) : 2475 - 2482
  • [35] Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn’s disease with anal endosonographic monitoring: a single-centre experience
    L. Guidi
    C. Ratto
    S. Semeraro
    I. Roberto
    I. De Vitis
    A. Papa
    M. Marzo
    A. Parello
    G. Foglietto
    G. B. Doglietto
    G. B. Gasbarrini
    G. Fedeli
    Techniques in Coloproctology, 2008, 12 : 111 - 117
  • [36] Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience
    Guidi, L.
    Ratto, C.
    Semeraro, S.
    Roberto, I.
    De Vitis, I.
    Papa, A.
    Marzo, M.
    Parello, A.
    Foglietto, G.
    Doglietto, G. B.
    Gasbarrini, G. B.
    Fedeli, G.
    TECHNIQUES IN COLOPROCTOLOGY, 2008, 12 (02) : 111 - 117
  • [37] Fistulizing Crohn's Disease Presenting After Surgery on a Perianal Lesion
    Singer, Andrew A. M.
    Gadepalli, Samir K.
    Eder, Sally J.
    Adler, Jeremy
    PEDIATRICS, 2016, 137 (03)
  • [38] Perianal Fistulizing Crohn's disease: imaging modalities and therapeutic challenges
    Katsanos, K. H.
    Papathanasopoulos, A. A.
    Christodoulou, D. K.
    Tsianos, E. V.
    ANNALS OF GASTROENTEROLOGY, 2009, 22 (04): : 255 - 262
  • [39] Failure of infliximab in fistulizing Crohn's disease
    Arora, S
    Wetzler, G
    Narwal, S
    JOURNAL OF INVESTIGATIVE MEDICINE, 2003, 51 : S415 - S415
  • [40] Prognostic factors for the efficacy of infliximab in patients with luminal fistulizing Crohn’s disease
    Ye Ma
    Runfeng Zhang
    Wei Liu
    Yinghao Sun
    Jingnan Li
    Hong Yang
    Hong Lv
    Yue Li
    Bei Tan
    Xiyu Sun
    Jiaming Qian
    Ji Li
    BMC Gastroenterology, 23